Meet John de Groot, M.D.
John F. de Groot, M.D.
Department of Neuro-Oncology, Division of Cancer Medicine Division
About Dr. de Groot
Dr. John de Groot is a Professor, and Chairman ad interim, in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. He is an expert in the fields of glioma angiogenesis and molecularly targeted therapy. He completed his medical education at The University of Texas Medical Branch at Galveston, and pursued internship and residency at Johns Hopkins School of Medicine. Following a clinical fellowship at MD Anderson, de Groot joined the faculty in 2004. His translational research program has produced critical insights into how gliomas respond to and resist killing by anti-angiogenic agents and illuminated therapeutic approaches employed in clinical trials to overcome this resistance. De Groot has also significantly contributed to the discovery of biomarkers of response and progression in glioblastoma patients treated with anti-angiogenic therapy, and as a result has opened multiple biomarker-driven clinical trials.
Dr. de Groot has served as the principal investigator (PI) or co-investigator on multiple funded National Cancer Institute, foundation, and industry-sponsored grants. He is the PI of numerous clinical trials involving novel agents being tested in patients with glioblastoma and is a leader of MD Anderson’s Glioblastoma Moon Shot. As director of the Neuro-Oncology Fellowship Program, he is also helping develop the next generation of neuro-oncologists.
Dr. de Groot has eighty peer reviewed articles. He is or has been a peer reviewer for 23 scientific journals, both national & international, and is on four editorial review boards.
Present Title & Affiliation
Primary Appointment
Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Chair ad interim, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1998 | The University of Texas Medical Branch at Galveston, Galveston, TX, USA, MD, Medicine |
| 1992 | Stanford University, Stanford, USA, BA, Human Biology |
Postgraduate Training
| 2002-2004 | Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1999-2002 | Clinical Residency, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
| 1998-1999 | Clinical Internship, Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD |
Board Certifications
| 2013 | United Council for Neurologic Subspecialties (UCNS) - Neuro-Oncology |
| 2002 | American Board of Psychiatry and Neurology |
Experience & Service
Institutional Committee Activities
Member, Graduate Medical Education (GME) Committee, 2008 - 2017
Selected Publications
Peer-Reviewed Articles
- Lee JH, Liu R, Li J, Zhang C, Wang Y, Cai Q, Qian X, Xia Y, Zheng Y, Piao Y, Chen Q, de Groot JF, Jiang T, Lu Z. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat Commun 8(1):949, 2017. e-Pub 2017. PMID: 29038421.
- Nam JY, de Groot JF. Treatment of Glioblastoma. J Oncol Pract 13(10):629-638, 2017. PMID: 29020535.
- Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol 18(9):1230-41, 2016. e-Pub 2016. PMID: 26965451.
- Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 17(8):1051-63, 2015. e-Pub 2015. PMID: 25934816.
- Martinez-Ledesma E, de Groot JF, Verhaak RG. Seek and destroy: relating cancer drivers to therapies. Cancer Cell 27(3):319-21, 2015. PMID: 25759016.
- Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci 353(1-2):92-7, 2015. e-Pub 2015. PMID: 25934342.
- Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 20(22):5612-9, 2014. PMID: 25398844.
- Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro Oncol 16(9):1289-94, 2014. e-Pub 2014. PMID: 24615863.
- Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep 14(5):443, 2014. PMID: 24652451.
- de Groot JF, Mandel JJ. Update on Anti-angiogenic Treatment for Malignant Gliomas. Curr Oncol Rep 16(4):380, 2014. PMID: 24510742.
- Chen SE, Choi SS, Rogers JE, Lei X, de Groot JF. Isotretinoin Maintenance Therapy for Glioblastoma: A Retrospective Review. J Oncol Pharm Pract 20(2):112-9, 2014. e-Pub 2013. PMID: 23676507.
- Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol 16(3):409-13, 2014. e-Pub 2013. PMID: 24305706.
- Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res 20(1):187-98, 2014. e-Pub 2013. PMID: 24240114.
- Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan A. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol 16(2):303-9, 2014. e-Pub 2013. PMID: 24311638.
- Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One 9(3):e91216, 2014. e-Pub 2014. PMID: 24614622.
- Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition. Clin Cancer Res 19(16):4392-403, 2013. e-Pub 2013. PMID: 23804423.
- Shonka N, Piao Y, Gilbert M, Yung WKA, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot JF. Cytokines associated with toxicity in treatment of recurrent Glioblastoma with Aflibercept. Target Oncology 8(2):117-125, 2013. e-Pub 2013. PMID: 23345034.
- Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, Tucker SL, Crawford CN, Khan M, Khatua S, Gilbert MR, Brown PD, Mahajan A. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 86(2):277-84, 2013. e-Pub 2013. PMID: 23433794.
- Kamiya-Matsuoka C, Garciarena P, Hesham MA, Tremont I, de Groot JF. B Lymphoblastic Leukemia/Lymphoma Presenting As Seventh Cranial Nerve Palsy. Neurology, 2013.
- Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF. Glioblastoma Resistance to Anti-VEGF Therapy is Associated with Myeloid Cell Infiltration, Stem Cell Accumulation, and a Mesenchymal Phenotype. Neuro Oncol 14(11):1379-1392, 2012. e-Pub 2012. PMID: 22965162.
- Theeler BJ, Yung WK, Fuller GN, de Groot JF. Moving Toward Molecular Classification of Diffuse Gliomas in Adults. Neurology 79(18):1917-1926, 2012. PMID: 23109653.
- de Groot JF, Liang J, Kong LK, Wei J, Piao Y, Fuller G, Qiao W, Hemberger AB. Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator Transcription 3 Pathway in Glioblastoma. Oncotarget 9(3):1036-48, 2012. PMID: 23013619.
- Walker GV, Li J, Mahajan A, McAleer MF, de Groot JF, Azeem SS, Brown PD. Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: A population-based analysis. Cancer 118(18):4538-44, 2012. e-Pub 2012. PMID: 22359097.
- Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, de Groot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. J Clin Oncol 28(11):1963-72, 2010. e-Pub 2010. PMID: 20231676.
- Ahluwalia MS, de Groot J, Liu W, Gladson CL. Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies. Cancer Letters 298(2):139-49, 2010. PMID: 20947248.
- Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy. Clin Cancer Res 15(14):4589-99, 2009. PMID: 19567589.
- Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via (beta) 1 integrin-dependent adhesion to the extracellular matrix. Neuro-Oncology 11(3):260-73, 2009. PMID: 18957620.
- Milano V, Piao Y, Lafortune T, de Groot J. Desatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Molecular Cancer Therapy 8(2):394-406, 2009. PMID: 19190119.
- Gonzales J, de Groot J. Combination therapy for malignant glioma based on PTEN status. Expert Rev Anticancer Therapy 8(11):1767-1779, 2008. PMID: 18983237.
- de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neuro-Oncology 90(1):89-97, 2008. PMID: 18581057.
- Gomez-Manzano C, Holash J, Fueyo J, Xu Jing, Conrad, CA, Aldape KD, de Groot JF, Bekele N, Yung WKA. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-Oncology 10(6):940-945, 2008. PMID: 18708344.
- de Groot J, Yung, WKA. Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas. Cancer J 14(5):279-285, 2008. PMID: 18836331.
- de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65(5):1934-40, 2005. PMID: 15753393.
- Grossman KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, de Groot JF, Aiken RD, Olsen JJ, Evans BA, Jensen RL. Phase I Trial of Verubulin (MPC-6827) plus carboplatin in Patients with Relapsed Glioblastoma Multiforme. Journal of Neuro Oncology. e-Pub 2012. PMID: 22932984.
- Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF. Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget. e-Pub 2016. PMID: 27050366.
- Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WKA. A Phase I Factorial Design Study of Dose-Dense Temozolomide Alone and in Combination with Thalidomide, Isotretinoin, and/or Celecoib as Postchemoradiation Adjuvant Therapy for Newly Diagnosed Glioblastoma. Neuro-Oncology 12(11):1167-72. e-Pub 2010. PMID: 20729242.
- Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res. e-Pub 2017. PMID: 29074604.
- Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. e-Pub 2014. PMID: 25388940.
Book Chapters
- de Groot JF, Yung, WK. Small Molecule Based Therapies. In Neuro-Oncology. In: Neuro-Oncology: The Essentials. 2nd. Thieme Publishers: New York, NY, 234-241, 2008.
Grant & Contract Support
| Title: | ImaRx Therapeutics Investigator Initiated Study "Enhancing drug delivery using ultrasound plus nanobubbles" |
| Funding Source: | ImaRX |
| Role: | Principal Investigator |
| Title: | Glutamate excitotoxicity, cystine and glioma growth |
| Funding Source: | American Brain Tumor Association (ABTA) - Basic Research Fellowship |
| Role: | Investigator |
| Title: | Deciphering Synergistic Combinatorial Targets in Glioma |
| Funding Source: | NIH/NCI/NINDS |
| Role: | Co-Investigator |
| Title: | Correlative Markers of Glioblastoma Response to VEGF Trap |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | The Role of AMPA Receptors in Glioma Proliferation and Invasion |
| Funding Source: | UTMDACC Institutional Research Grant-IRG |
| Role: | Principal Investigator |
| Title: | Predictors of Glioblastoma Response to VEGF Trap |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | SPORE in Brain Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | The effect of CT-322 on glioma biology and growth in an in vivo glioma stem cell model |
| Funding Source: | Adnexus |
| Role: | Principal Investigator |
| Title: | Preclinical Validation of Targeting Macrophage CSF-1R in Glioblastoma |
| Funding Source: | AstraZeneca Research Collaboration Alliance |
| Role: | Principal Investigator |
| Title: | Adaptive selection design with molecular subset analysis: A Bayesian paradigm to optimize treatment success for patients with glioblastoma |
| Funding Source: | The Ben and Catherine Ivy Foundation |
| Role: | Co-Investigator |
| Title: | Modulation of Resistance to Antiangiogenic Therapy: A Clinical Trial with Correlative Studies |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Preclinical Validation of Targeting the JAK/STAT Pathway in Glioma with AZD1480 |
| Funding Source: | AstraZeneca |
| Role: | Investigator |
| Title: | SPORE DRP- Targeting the JAK2/STAT-3 Pathway in Glioma to Overcome Resistance to Antiangiogenic Therapy |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| Title: | Evaluation of XL765 for the Prevention of Glioblastoma Resistance to Bevacizumab Therapy |
| Funding Source: | Sanofi-Aventis |
| Role: | Principal Investigator |
| Title: | Preclinical Validation of Targeting P70S6K/AKT with MSC3318 |
| Funding Source: | EMD Serono |
| Role: | Principal Investigator |
| Title: | Molecular Predictors of Response to Targeted Therapy in Glioblastoma: Preclinical Validation of Eli Lilly Compounds Targeting CDK4/6, SHH, FGFR, cMET, and p38-MAPK |
| Funding Source: | Eli Lilly |
| Role: | Principal Investigator |
| Title: | Ivy CTC Virtual Tissue Bank for Malignant Glioma Patients |
| Funding Source: | Ivy Foundation Early Phase Clinical Trials Consortium |
| Role: | Principal Investigator-MDACC |
| Title: | Evaluation of Novartis oncology compounds to validate specific targeted therapies in glioblastoma with unique subtype and molecular profiles |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| Title: | SPORE for Brain Tumors: Animal Core (Core E) |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
Dr. John de Groot is a neuro-oncologist specializing in the treatment of primary brain tumors, including glioblastoma.
Dr. John de Groot sees patients in the Brain and Spine Center at MD Anderson.
Dr. de Groot presents an update on his Brain Cancer SPORE grant project team's research.